ARAMIS Patient Summary

 PHEN Clinical Trials Rally

 

Patients should consider the ARAMIS trial if hormone therapy treatments, such as Lupron, no longer keep their PSA from rising but their doctor has not detected any prostate cancer spread to other parts of the body. This is called high-risk non-metastatic castration-resistant prostate cancer. 

Patients who participate in the ARAMIS trial are randomly (by chance) assigned to receive the experimental drug BAY1841788 (ODM-201) or a placebo to determine if the experimental drug is effective in keeping prostate cancer from progressing. Neither the researchers nor the participants can choose or know who is assigned to which group.

ARAMIS is a phase 3 clinical trial which will enroll 1500 patients. The trial began in 2014 and the primary completion date is 2018.

Possible patient benefits include slowing the spread (progression) of prostate cancer to other parts of the body and prolonging life.

If you are interested in this trial you can take these actions:

  • Use the "clinical trials glossary" and "dictionary" for words, phrases and treatments that you may not understand.
PHEN Contact: 617-481-4020 x3

ARAMIS Sponsor:
Bayer; Contact: 646-776-7532 or 844-229-3710 (toll free), email: 
Bayer@emergingmed.com

 
* Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.



Go Back





PHEN,Inc. © 2017 All rights reserved